![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
Previous Article | Next Article 
Infection and Immunity, September 2006, p. 5095-5105, Vol. 74, No. 9
0019-9567/06/$08.00+0 doi:10.1128/IAI.00598-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
*
Xin-He Lai,
Lidia Crosa,
Briana Kozlowicz, and
Fred Heffron
Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon
Received 12 April 2006/ Returned for modification 17 May 2006/ Accepted 5 June 2006
 |
ABSTRACT |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
INTRODUCTION |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Although the molecular mechanisms of F. tularensis pathogenesis remain relatively obscure, it has been established that replication in human and animal macrophages is central to this organism's ability to cause tularemia (14). Several F. tularensis genes associated with intracellular growth have been identified, including iglB, iglC, mglA, pdpD, and a clpB homolog (2, 18, 20, 31, 33). Additionally, it is thought that many of the genes in the recently described F. tularensis pathogenicity island (FPI) contribute to the survival and growth of this organism in macrophages (32, 35). Of these, only iglC has been studied as the basis for a potential vaccine strain. Pammit et al. recently reported that intranasal vaccination with an F. novicida strain carrying an iglC deletion resulted in >50% protection against challenges with the wild-type organism (38). However, the capacity of mutant derivative strains with mutations in other FPI genes to confer protection against challenge with wild-type bacteria has not been studied.
Three main subspecies of F. tularensis are commonly recognized: F. tularensis subsp. tularensis (type A), F. tularensis subsp. holarctica (type B), and F. tularensis subsp. mediasiatica. All of these biotypes along with F. novicida exhibit more than 95% DNA sequence identity (3). Although type A and type B strains are highly infectious, only type A strains cause significant mortality in humans. The current live vaccine strain (LVS) is an attenuated type B strain that provides different levels of protection against challenge with type A F. tularensis strains depending on the route of immunization, the route of challenge, and the genetic background of the host (4-6, 21, 43, 49). Because the molecular basis for LVS attenuation is not known, this strain is not licensed as a tularemia vaccine.
F. novicida U112 provides an ideal model for studying Francisella pathogenesis for several reasons. While F. novicida is not considered a human pathogen, it exhibits a degree of virulence in mice similar to that of F. tularensis subspecies (27, 42). Moreover, F. novicida is easier and less dangerous to manipulate genetically than F. tularensis. In addition to the considerable genomic similarity (>95%), the close relationship between F. novicida and F. tularensis is further highlighted by their nearly identical 16S rRNA gene sequences (13). The degree of genetic identity suggests that the two organisms utilize similar virulence genes and that F. novicida is thus an apt platform for the development of a tularemia vaccine.
In this study, we used transposon mutagenesis to identify F. novicida genes required for intracellular growth. The resulting mutant strains were screened for attenuation in macrophages and mice and tested for the ability to provide protection against a wild-type challenge in mice. Five F. novicida mutant strains were found to protect mice against challenge with >8 x 105 CFU of wild-type F. novicida. These results will be used in the future for construction of a Francisella vaccine.
|
MATERIALS AND METHODS |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Generation of bacterial transposon mutant strains.
A library of F. novicida transposon insertion mutants was created by electroporating mini-Tn5 transposon-transposase complexes into appropriately prepared F. novicida. Although independently developed, our technique was similar to that of Kawula et al. (26, 45). The mini-Tn5 cycler transposon was constructed as previously described (17). The transposon-transposase complex was prepared as described by Goryshin et al. (19). F. novicida U112 was grown to confluence on CHA plates at 37°C and resuspended with 5 ml of ice-cold 10% glycerol-500 mM sucrose buffer. Aliquots (1 ml) were transferred to 1.5-ml microcentrifuge tubes, pelleted by centrifugation at 12,000 x g for 5 min at 4°C, and resuspended in 1 ml of buffer. This wash step was repeated until a total of four washes had been performed. After the final wash, each aliquot was resuspended in 100 µl buffer. One microliter of transposon-transposase complex was added to each tube, and the samples were electroporated in 1-mm-gap cuvettes at 1.5 to 1.7 kV, 200 
, and 25 µF. The bacteria were recovered in 1 ml TSBC in glass tubes for 4 h in a 37°C rotator and plated on CHA/Kan20 plates. The frequency of isolation of transposon insertion mutants was rather low (about 10 to 100 insertions per 109 cells following electroporation).
Culture and infection of cell lines and primary macrophages. The J774A.1 and RAW264.7 murine macrophage cell lines (American Type Culture Collection, Manassas, VA) were cultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco-BRL, Rockville, MD) supplemented with 10% fetal bovine serum (FBS) (Gibco-BRL), 1 mM nonessential amino acids (Gibco-BRL), and 0.2 mM sodium pyruvate (Gibco-BRL) at 37°C in the presence of 5% CO2. Bone marrow-derived macrophages (BMDM) were collected by flushing the femurs of BALB/c mice with serum-free DMEM and were cultured in DMEM supplemented with 20% L929 and an antibiotic cocktail of penicillin (10,000 U/ml) and streptomycin (10,000 µg/ml). For infection, bacteria were added to 50% confluent cells in 24- or 96-well culture dishes (Corning, Corning, NY) or four-chamber microscope plates (Nalge Nunc, Naperville, IL) at the multiplicities of infection (MOI) indicated below, and the cells were centrifuged at 1,000 x g for 5 min at room temperature and incubated at 37°C in the presence of 5% CO2. One hour after infection, the cells were washed twice with phosphate-buffered saline (PBS), and DMEM containing 100 µg/ml of gentamicin was added to prevent the growth of any extracellular bacteria (29). Two hours after infection, the cells were washed twice with PBS and either lysed or incubated in the presence of 10 µg/ml gentamicin for an additional 22 h. Cells were lysed with TSBC containing 0.5% saponin (Sigma) for 30 min at 37°C in the presence of 5% CO2.
Screening for reduced growth in macrophages.
RAW macrophages were seeded to obtain 50% confluence in 96-well tissue culture plates and infected (MOI of 
1,000) with overnight cultures of F. novicida mutant strains that were grown in stationary 96-well tissue culture plates, as described above. At 24 h postinfection (p.i.), the macrophages were washed and lysed as described above. Three percent of each lysate was plated onto CHA/Kan20 plates and incubated overnight at 37°C. Mutants that exhibited growth defects were identified visually. To eliminate false positives, the potentially attenuated mutants were subjected to another round of selection by infecting RAW macrophages in 24-well plates, as described above, using an input MOI of 100, which corresponded to about one bacterium per macrophage. After lysis, 50 µl of each lysate was plated onto CHA plates and incubated overnight at 37°C. F. novicida mutants compromised for growth in macrophages were identified visually by comparison to wild-type U112 infection lysates; the attenuated mutants yielded individual colonies, while the wild-type bacteria grew to confluence.
Sequencing of mini-Tn5 insertion sites and sequence analysis. The method described by Geddes et al. was used for sequencing mini-Tn5 insertion sites and sequence analysis (17). Briefly, chromosomal DNA from F. novicida mutants exhibiting reduced growth in macrophages was prepared (1), digested with EcoRI, and subcloned into pACYC184. Ligation reaction mixtures were electroporated into GeneHogs E. coli cells (Invitrogen) and selected for growth on LB medium containing 60 µg/ml kanamycin. Plasmids from kanamycin-resistant colonies were purified using a QIAprep Spin miniprep kit (QIAGEN, Valencia, CA) according to the manufacturer's instructions. The DNA sequence of the fusion junction was obtained using a primer complementary to bp 166 to 190 of the 5' end of mini-Tn5 cycler (5' GTTGACCAGGCGGAACATCAATGTG 3'). Sequence analysis was performed using the MacVector 7.2.3 software and the NCBI BLAST server at http://www.ncbi.nlm.nih.gov/BLAST/.
Mouse studies. Six- to 8-week old female BALB/c mice were purchased from the Jackson Laboratory (Bar Harbor, ME). The animals were fed autoclaved food and water ad libitum. All experiments were performed in accordance with Animal Care and Use Committee guidelines. For vaccination and challenge studies, mice were inoculated intraperitoneally (i.p.) with bacteria in 150 µl (total volume) of PBS. Mice were vaccinated with the number of CFU indicated below. Surviving mice were challenged 28 days later with the doses indicated below. Dissemination and clearance of the bacteria were determined by harvesting the lungs, liver, and spleen on the days postinfection indicated below, homogenizing the organs with a stomacher, and plating serial dilutions. The 50% lethal doses (LD50) were calculated by the method of Reed and Muench (39). Mice were checked for signs of illness or death twice each day following infection.
Bacterial growth in liquid media. Overnight cultures of F. novicida were diluted into 10 ml of TSBC to obtain an optical density at 600 nm (OD600) of 0.1. Optical densities were then recorded at the times specified below. Note that the cultures were diluted 1:10 to obtain OD600 of >1 for accuracy. We previously determined by plating that an OD600 of 1 was equivalent to approximately 4 x 109 bacteria/ml.
Quantification of bacterial entry and growth in macrophages. J774 and RAW cells and BMDM were seeded in triplicate to obtain 50% confluence in 24-well tissue culture plates and were infected as described above with F. novicida mutant strains at an input MOI of 100. Cells were lysed at 2 or 24 h p.i. Serial dilutions of the lysates were plated onto CHA/Kan20 or CHA (wild-type and mock infection controls) plates. After overnight incubation at 37°C, the colonies on each plate were counted. Means and standard deviations were calculated using Microsoft Excel X for Mac. The 24-h data were statistically analyzed by paired two-tailed t tests using Microsoft Excel X for Mac.
Southern blot analysis. F. novicida chromosomal DNA was prepared using the cetyltrimethylammonium bromide method (1), and 250 ng of each preparation was digested to completion with HindIII. Digested DNA was electrophoresed on a 0.8% agarose gel for 2 h at 90 kV and then transferred to a positively charged nylon membrane (Roche) using a standard capillary transfer method (1). DNA was cross-linked to the membrane at 120,000 µJ/cm2 using a Stratalinker 1800 UV cross-linker (Stratagene, La Jolla, CA). The digested bacterial DNA was probed with a digoxigenin-labeled probe using a DIG High Prime II DNA labeling and detection starter kit (Roche, Indianapolis, IN), and the membrane was exposed to film (Kodak, Rochester, NY) for 2 or 8 min as described below. By using a DNA probe that spans a HindIII site in the transposon and hybridizes to two separate locations of the HindIII-digested chromosomal DNA, we were able to determine the number of transposon inserts in each strain.
Cytotoxicity assay. A cytotoxicity assay was conducted as described by van der Velden et al. (48). Briefly, J774 cells seeded in 96-well culture plates were infected in triplicate with either the transposon mutants or wild-type F. novicida U112 at an input MOI of 100. After 48 h, the supernatants were removed and assayed for released lactate dehydrogenase (LDH) using the CytoTox 96 nonradioactive cytotoxicity assay (Promega, Madison, WI). Cytotoxicity was determined for each mutant strain by calculating the amount of LDH released as a percentage of the maximal amount released from macrophages infected with wild-type strain U112.
Microscopy. J774 cells were infected at an input MOI of 100, as previously described, in four-well chamber plates (Nalge Nunc). After 24 h, the cells were washed twice with PBS, fixed for 1 h with 4% paraformaldehyde, and stored in PBS at 4°C. After three washes for 10 min in PBS, the cells were permeabilized with 0.5% Triton X-100 (Sigma Chemical) in PBS for 20 min at room temperature, blocked with 5% FBS in PBS for 30 min, and incubated for 1 h at 4°C with a polyclonal antibody against F. tularensis (Becton, Dickinson and Company). After three washes for 10 min in PBS, the cells were again blocked with 5% FBS. A goat anti-rabbit antibody conjugated to Alexa 488 (Molecular Probes, Eugene, OR) was applied to the cells overnight at 4°C. The cells were again washed three times for 10 min in PBS and incubated with a 1:1,000 dilution of FM 4-64 membrane stain (Molecular Probes) and 1:1,000 dilution of Draq5 DNA stain in PBS (Alexis Biochemicals, San Diego, CA) for 10 min at room temperature. The cells were washed twice with PBS and mounted in Fluormount-G antifade solution (Southern Biotechnology, Birmingham, AL), and images were obtained with an Applied Precision DeltaVision deconvolution microscope system (Advanced Precision Instruments, Issaquah, WA). All images were taken obtained a x60 objective. Stacks of 10 z-plane images that were 1 µm apart were captured at 1024 x 1024 pixels and deconvolved for seven iterations. Selected images were saved in TIFF format and imported into Adobe Photoshop to be formatted.
Complementation of disrupted genes. Plasmid pKK202 (30) was modified to include unique NotI, SfiI, and XhoI restriction sites by digestion with ClaI and XbaI, followed by ligation with a DNA fragment. Oligonucleotides CGGCGGCCGCTTGGCCTCGAGGGCC and CTAGGGCCCTCGAGGCCAAGCGGCCGC were annealed to obtain a double-stranded product encoding the new restriction sites. Using SCHU S4 DNA as a template, full-length genes were amplified by PCR. The dsbB gene was cloned using primers GCGGCCGCCTTCTTAACGTCCACAGTTTTGTCC and GGCCCTCGAGGCCCTTTCTGATGGTTTGTCATTTCTCC, FTT0742 was cloned using primers GCGGCCGCGCAGCATTACCTGGAATTACAAG and GGCCCTCGAGGCCCAAACAGCAAATAAATATACAACACC, and fumA was cloned using primers GCGGCCGCTAGTGATAAAATTAGCGAGG and GGCCCTCGAGGCCATTAACTATAATGCCGAG. The modified pKK202 vector and the PCR products were digested with NotI and XhoI and ligated. pKK202-dsbB was electroporated into the dsbB mutant F. novicida strain and used to infect J774 and RAW cells, primary macrophages, and mice as indicated below. pKK202-FTT0742 and pKK202-fumA were similarly tested with RAW cells.
|
RESULTS |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Macrophages are the primary host cell type for Francisella in both humans and animals (14). It follows that one approach for developing a tularemia vaccine would be to discern which Francisella genes are necessary for growth in macrophages. Thus, we screened our F. novicida transposon mutant library for mutants that had a reduced ability to grow in macrophages, as described in Materials and Methods. Of the more than 700 F. novicida transposon mutants screened, 34 exhibited reduced growth in RAW macrophages. We obtained sequences for 28 of these mutant strains and identified the disrupted open reading frames (ORFs) by comparison to the SCHU S4 sequence (Table 1).
|
Five F. novicida mutants protected mice against challenge. The ideal living vaccine strain produces an asymptomatic infection that provides complete protection against subsequent exposure to the wild-type organism. To determine if any of our 16 attenuated F. novicida transposon mutants could confer protection against wild-type infection, we next challenged the surviving vaccinated mice with the wild-type parental strain. Four weeks after infection with mutant F. novicida strains, surviving mice were intraperitoneally challenged with 8 x 105 CFU F. novicida U112. We considered this to be a very stringent challenge, as the dose was more than 10,000 times the LD50 observed for wild-type infection. At 28 days after the challenge, 5 of the 16 mutants exhibited 100% protection after a single vaccination; these mutants had mutations in dsbB, the ORF corresponding to FTT0742 (referred to as FTT0742 below), pdpB, fumA, and carB (Table 2). In the same experiments, all wild-type control infections resulted in 0% survival.
|
|
In J774 mouse macrophage-like cells, the levels of entry were quite similar for the mutant and wild-type strains, except for the pdpB mutant (Fig. 1A). The dsbB mutant exhibited the highest level of attenuation in J774 cells, and for the FTT0742 mutant derivative there was also a decrease in the number of CFU after 24 h. Although fewer pdpB mutant bacteria than bacteria of the other strains entered J774 cells, this mutant still displayed an attenuation phenotype. For the fumA mutant there was very little difference between the level of entry and the level of replication at 24 h, indicating that there was no death, no replication, or a balance between the two. Interestingly, the carB mutant was able to replicate within J774 cells, albeit at a lower rate than the wild-type control. Each of the mutants exhibited statistically significant attenuation in J774 cells at 24 h p.i. (P < 0.005).
|
As observed for the J774 and RAW cells, the dsbB and pdpB mutants were the most attenuated strains in primary murine BMDM (Fig. 1C). Despite its high LD50 for mice, the ability of the FTT0742 mutant derivative to enter or replicate within BMDM was not impaired, and both the fumA and carB strains displayed only slight attenuation. This apparent disparity underlies the differences in infection among various cell populations. It should also be noted that the BMDM were not stimulated prior to infection and were probably less microbicidal than tissue-resident macrophages in the mouse model. In BMDM, only the dsbB, pdpB, and carB strains were significantly attenuated for growth at 24 h p.i. (P < 0.01).
To visually assess the replication of F. novicida transposon mutants in macrophages, fluorescence microscopy was performed. J774 macrophages were infected and prepared for microscopy as described in Materials and Methods. As expected, macrophages infected with F. novicida U112 contained more bacteria than cells infected with our mutants contained (Fig. 2). Although several bacteria were observed inside host cells infected with the fumA mutant (Fig. 2F), infections with the dsbB, FTT0742, pdpB, and carB mutant strains resulted in only one or two intracellular bacteria at 24 h p.i. These findings corroborated our finding that the F. novicida transposon mutants were defective for replication or survival inside macrophages. Furthermore, although the macrophages were initially seeded at the same concentration, fewer cells remained in the wells after infection with wild-type strain U112 than after infection with the mutants and in uninfected controls. This observation indicated that host cell death occurred during the course of the wild-type infection but not during infection with attenuated mutant strains.
|
Infection with F. novicida mutants did not reduce host cell integrity. The observed attenuation phenotypes could have been a result of increased host cell killing, which would have yielded fewer live infected macrophages and thus fewer bacteria, as they would have been killed by the gentamicin in the extracellular media (29). One method for determining the degree of cytotoxicity that results from bacterial infection is to measure cell lysis by quantifying the release of the stable cytosolic enzyme LDH. J774 macrophages were infected with either wild-type strain U112 bacteria or one of the five mutant strains for 48 h at an input MOI of 100. The levels of LDH in the supernatants were then recorded. As shown in Fig. 3, the abilities of the five mutant strains to cause cell lysis were significantly impaired compared with the ability of wild-type F. novicida. With the levels of LDH released during wild-type infection normalized to 100%, the amounts of LDH released during infection with the five attenuated mutants ranged from 9.75% (FTT0742) to 24.52% (fumA). These results indicated that the attenuation phenotypes were not due to increased killing of host cells by the transposon mutants and that the intracellular replication of these strains was indeed compromised.
|
|
|
|
The dsbB gene was amplified from SCHU S4 DNA by PCR and cloned into plasmid pKK202 (30). Following transformation into the dsbB mutant, the abilities to replicate within macrophages and cause disease in mice were determined. As shown in Fig. 6, in trans expression of the cloned dsbB gene provided nearly complete complementation of the virulence defect in three different cell types. Further analysis showed that the LD50 was 60.25 CFU, which is comparable to the wild-type LD50 (66.25 CFU).
|
Like complementation of the dsbB mutation, complementation of the fumA mutation with the full-length gene restored the level of intracellular growth to the level of wild-type F. novicida (Fig. 6E). Taken together, these findings show that the observed attenuation phenotypes were due to mutations in dsbB, FTT0742, and fumA.
Complementation of pdpB will be attempted in the future, as the transposon insertion is located in the second gene of a 12-gene operon and is undoubtedly polar on expression of downstream genes. Based on its in vitro growth defect, comparatively low LD50, relative lack of intracellular attenuation, and questionable dissemination patterns, we felt that the carB mutant was not a strong enough candidate to include in further development of a vaccine against tularemia, and therefore we did not attempt to complement the carB gene.
Mutant strains protected mice against very high doses of wild-type bacteria. To further assess the level of protection provided by the F. novicida transposon insertion mutants, we challenged vaccinated mice with higher doses of the wild-type U112 parental strain. The dsbB, FTT0742, pdpB, and fumA mutant strains were used to infect groups of five mice, and the doses used were 6 x 105, 6 x 106, and 6 x 107 CFU (Table 4). Mice infected with each of the three doses of our FTT0742 and pdpB mutants had a survival rate of 100%, as did the animals infected with the lowest doses of the dsbB and fumA mutants. Four weeks after vaccination, surviving animals were challenged with 6 x 107 CFU of wild-type strain F. novicida U112, which is approximately 106 times the observed LD50 for wild-type infection. All of the mice challenged survived without any symptoms of disease. These results demonstrated that four of our F. novicida transposon mutants were capable of protecting mice against infection with very high levels of the wild-type organism. Overall, our findings indicate that Francisella strains carrying mutations in these genes are candidates for a vaccine against tularemia.
|
DISCUSSION |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Disulfide bond formation protein B is encoded by dsbB. This integral membrane protein is part of a pathway that leads to disulfide bond formation between cysteine residues in periplasmic proteins in E. coli and other bacteria (23). The functional folded conformation of a protein often relies upon correct disulfide pairing of the cysteine residues. Thus, one explanation for why our dsbB mutant strain is attenuated is that a protein(s) required for replication inside host cells does not achieve its active conformation. It is also exciting to speculate that, with its potential influence on periplasmic proteins, the dsbB gene product may be involved in the secretion of virulence factors, possibly to ensure correct folding of components of a secretion apparatus.
The FTT0742 ORF codes for a hypothetical lipoprotein that is predicted to have transmembrane regions. Therefore, it is possible that the gene product is a component of the F. novicida cell wall and/or may be involved in molecule transport. Because in vitro growth and entry into the host cell were not compromised, we speculate that FTT0742 affects a function necessary for virulence and growth inside macrophages. Characterization of the FTT0742 protein should further clarify its role in virulence.
The product of the pdpB gene is an uncharacterized protein encoded on the FPI that exhibits some similarity to the conserved bacterial protein IcmF (http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi). It has been shown that icmF is required for Legionella pneumophila intracellular growth, so we hypothesized that pdpB plays a similar role in F. novicida intracellular growth (50). Also of note, this gene exhibits some similarity to the genes encoding rhoptry proteins of the parasite Plasmodium, which mediate attachment to host red blood cells (40). Although the pdpB mutant did not exhibit defects during in vitro growth, its ability to enter host cells was significantly compromised and it displayed prominent intracellular attenuation since no CFU were detected in the lysates of RAW and J774 cells at 24 h p.i. Because pdpB is the second ORF in a 12-gene operon, it is likely that the transposon insert in this gene has polar effects on downstream genes. These findings indicate that pdpB or other genes in the pdp operon are needed for both entry into and replication within host cells. So far, the functions of the genes in the pdp operon have not been elucidated.
Fumarate hydratase A, the component of the Kreb's cycle (citric acid cycle) that converts fumarate to malate, is encoded by fumA (46). The citric acid cycle is one of the three metabolic pathways of cellular respiration and is necessary for fuel catabolism and ATP production. Precursory molecules for compounds such as amino acids are also generated by the citric acid cycle. Thus, the observation that our fumA mutant exhibited lower levels of in vitro replication than wild-type strain U112 exhibited may have been a result of energy deficiency or a lack of molecules needed for replication.
The carB gene encodes the large subunit of the heterodimeric enzyme carbamoyl phosphate synthase, which is required for pyrimidine biosynthesis (28). As pyrimidines are required for replication, it is clear that a mutation in this biosynthesis pathway would lead to both in vitro and intracellular growth defects. Indeed, we observed an in vitro growth defect with this mutant strain. Nevertheless, our carB mutant was able to infect macrophages and protect mice against challenge with the wild-type organism, which suggests that strains with mutations in the pyrimidine pathways of F. novicida may be useful as potential vaccine strains. However, compared to the other F. novicida mutants used in this study, the carB mutant had a lower LD50 and less intracellular attenuation and did not appear to disseminate from the initial site of infection. For these reasons, we decided not to pursue use of this mutant as a possible vaccine candidate.
Although we observed only partial complementation of the FTT0742 mutant phenotype, we still consider this strain to be a vaccine candidate. Complementation experiments similar to those described in this paper carried out with Salmonella have also resulted in mixed success because the copy number of the plasmid, as well as the regulation of the gene itself, can influence complementation. In fact, the Forsberg group recently demonstrated the importance of correct gene regulation during complementation in Francisella with their studies of pilA; there was functional complementation in cis, but expression of PilA was barely detectable in the strain complemented in trans (12). The problem was further compounded in our studies because the F. novicida genome has not been published yet; therefore, the genes used for complementation were amplified from SCHU S4 DNA and may be incompatible with F. novicida due to variations between the subspecies.
Intriguingly, another finding of this study was the lack of protection conferred by pur mutants in a murine model. It has been postulated previously that mutations affecting the F. tularensis purine synthesis pathway could be used to generate a live attenuated tularemia vaccine (25). In fact, defined allelic replacement mutants with mutations that disrupt this pathway have been used to produce vaccine strains attenuated for replication in host cells in a variety of other bacterial species (36). Our F. novicida transposon library contained eight unique pur mutants, including mutants with mutations in purA, a purCD fusion (two strains), purL (two strains), and purM (three strains). Each of these strains exhibited 100% attenuation in mice when 6 x 103 CFU was used, yet all of them failed to protect mice against a wild-type parental challenge with 8 x 105 CFU. Although these results do not necessarily eliminate purine biosynthesis mutants as potential live vaccine strains, it was noteworthy that these mutants did not protect against challenge with wild-type F. novicida strain U112.
As an alternative to live vaccines, the possibility of developing a subunit vaccine must also be examined. Studies in which the efficacy of whole killed cells as a crude tularemia vaccination was evaluated demonstrated the feasibility of a subunit vaccine and prompted research into identification of antigens that induce protective immunity (8, 24). Although several polysaccharide and protein components of F. tularensis have been shown to react with convalescent-phase sera or T cells (22), the only antigen that has exhibited the ability to induce a protective immune response against tularemia is lipopolysaccharide (36). However, the protection was effective only against F. tularensis subsp. holarctica strains and was incomplete (7, 15, 16). Protection against a highly virulent F. tularensis type A strain likely depends on a Th1-mediated cellular immune response (44). So far, there is no way to administer antigens or killed bacteria that are as effective as a living attenuated vaccine, a point that has been highlighted by work in the Pamer laboratory showing that the immune system distinguishes between living and dead bacteria (37).
In contrast, a live attenuated vaccine would be effective in inducing the appropriate cellular responses (36). In fact, the type B LVS strain provides the only current means of tularemia vaccination. However, several limitations prevent the licensing of this vaccine. Foremost among these constraints is the fact that the genetic basis of LVS attenuation and protection remains unknown. Second, culturing LVS under certain conditions can lead to poorly immunogenic colony variants, which demonstrates this organism's inherent genetic instability (9, 11). Also, this vaccine does not provide protection to every individual vaccinated (34, 41). Finally, LVS protection against aerosol challenge is variable and depends on the route of immunization, as well as the host (4-6, 43). The last point is especially critical when F. tularensis is considered as a biological weapon, as aerosol dispersal is the most likely route of delivery. Taken together, these limitations clearly show that the development of an approved tularemia vaccine requires the development of a rationally attenuated, nonreverting live vaccine strain.
While the manuscript was in preparation, the Conlan Sjöstedt groups published the first description of a defined gene deletion mutant of a type A strain that protected mice against challenge with the wild-type organism (47). Indeed, the ideal live vaccine strain would be derived from a virulent F. tularensis strain; however, we used F. novicida as a model for preliminary analysis of potential tularemia vaccines because this taxon is more amenable to genetic manipulation without the danger of infection. Furthermore, because all of the Francisella taxa are closely related (3), genes necessary for intracellular growth in F. novicida are likely to have the same function in F. tularensis. Consequently, F. novicida strains provide relatively safe, genetically significant organisms with which to conduct exploratory investigations prior to studies with the more virulent F. tularensis subspecies.
Here, we describe discovery of five F. novicida transposon mutants that exhibit attenuation in macrophages and are capable of protecting mice against infection with the wild-type parental strain at doses that are up to 106 times the observed wild-type LD50. An approved tularemia vaccine must be a highly attenuated nonreverting derivative of a type A strain, as such strains are most likely to be used in a bioterrorism attack and there is no certainty that one taxon will protect against another. Accordingly, we will now focus on extending this work to Francisella type A strains by creating deletions of each of the genes identified here and assaying for virulence in a mouse model.
|
ACKNOWLEDGMENTS |
|---|
This work was supported by NIH R21 grant EB000985 to F.H., as well as by a National Science Foundation Graduate Research Fellowship and a OHSU Tartar Trust Fellowship, both to R.T.
|
FOOTNOTES |
|---|
R.T. and X.-H.L. contributed equally to this work.
|
REFERENCES |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
| 1. | Ausubel, F. M. 2002. Short protocols in molecular biology: a compendium of methods from Current Protocols in Molecular Biology, 5th ed. Wiley, New York, NY. |
| 2. | Baron, G. S., and F. E. Nano. 1998. MglA and MglB are required for the intramacrophage growth of Francisella novicida. Mol. Microbiol. 29:247-259.[CrossRef][Medline] |
| 3. | Broekhuijsen, M., P. Larsson, A. Johansson, M. Bystrom, U. Eriksson, E. Larsson, R. G. Prior, A. Sjostedt, R. W. Titball, and M. Forsman. 2003. Genome-wide DNA microarray analysis of Francisella tularensis strains demonstrates extensive genetic conservation within the species but identifies regions that are unique to the highly virulent F. tularensis subsp. tularensis. J. Clin. Microbiol. 41:2924-2931. |
| 4. | Chen, W., R. KuoLee, H. Shen, and J. W. Conlan. 2004. Susceptibility of immunodeficient mice to aerosol and systemic infection with virulent strains of Francisella tularensis. Microb. Pathog. 36:311-318.[CrossRef][Medline] |
| 5. | Chen, W., H. Shen, A. Webb, R. KuoLee, and J. W. Conlan. 2003. Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background. Vaccine 21:3690-3700.[CrossRef][Medline] |
| 6. | Conlan, J. W., H. Shen, R. Kuolee, X. Zhao, and W. Chen. 2005. Aerosol- but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma-dependent mechanism. Vaccine 23:2477-2485.[CrossRef][Medline] |
| 7. | Conlan, J. W., H. Shen, A. Webb, and M. B. Perry. 2002. Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen. Vaccine 20:3465-3471.[CrossRef][Medline] |
| 8. | Coriell, L. L., E. O. King, and M. G. Smith. 1948. Studies on tularemia IV. Observations on tularemia in control and vaccinated monkeys. J. Immunol. 58:183-202. |
| 9. | Cowley, S. C., S. V. Myltseva, and F. E. Nano. 1996. Phase variation in Francisella tularensis affecting intracellular growth, lipopolysaccharide antigenicity and nitric oxide production. Mol. Microbiol. 20:867-874.[CrossRef][Medline] |
| 10. | Dennis, D. T., T. V. Inglesby, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. D. Fine, A. M. Friedlander, J. Hauer, M. Layton, S. R. Lillibridge, J. E. McDade, M. T. Osterholm, T. O'Toole, G. Parker, T. M. Perl, P. K. Russell, and K. Tonat. 2001. Tularemia as a biological weapon: medical and public health management. JAMA 285:2763-2773. |
| 11. | Eigelsbach, H. T., and C. M. Downs. 1961. Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J. Immunol. 87:415-425. |
| 12. | Forslund, A. L., K. Kuoppa, K. Svensson, E. Salomonsson, A. Johansson, M. Bystrom, P. C. Oyston, S. L. Michell, R. W. Titball, L. Noppa, E. Frithz-Lindsten, M. Forsman, and A. Forsberg. 2006. Direct repeat-mediated deletion of a type IV pilin gene results in major virulence attenuation of Francisella tularensis. Mol. Microbiol. 59:1818-1830.[CrossRef][Medline] |
| 13. | Forsman, M., G. Sandstrom, and A. Sjostedt. 1994. Analysis of 16S ribosomal DNA sequences of Francisella strains and utilization for determination of the phylogeny of the genus and for identification of strains by PCR. Int. J. Syst. Bacteriol. 44:38-46.[CrossRef][Medline] |
| 14. | Fortier, A. H., S. J. Green, T. Polsinelli, T. R. Jones, R. M. Crawford, D. A. Leiby, K. L. Elkins, M. S. Meltzer, and C. A. Nacy. 1994. Life and death of an intracellular pathogen: Francisella tularensis and the macrophage. Immunol. Ser. 60:349-361.[Medline] |
| 15. | Fulop, M., R. Manchee, and R. Titball. 1995. Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularemia. Vaccine 13:1220-1225.[CrossRef][Medline] |
| 16. | Fulop, M., P. Mastroeni, M. Green, and R. W. Titball. 2001. Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine 19:4465-4472.[CrossRef][Medline] |
| 17. | Geddes, K., M. Worley, G. Niemann, and F. Heffron. 2005. Identification of new secreted effectors in Salmonella enterica serovar Typhimurium. Infect. Immun. 73:6260-6271. |
| 18. | Golovliov, I., A. Sjostedt, A. Mokrievich, and V. Pavlov. 2003. A method for allelic replacement in Francisella tularensis. FEMS Microbiol. Lett. 222:273-280.[Medline] |
| 19. | Goryshin, I. Y., J. Jendrisak, L. M. Hoffman, R. Meis, and W. S. Reznikoff. 2000. Insertional transposon mutagenesis by electroporation of released Tn5 transposition complexes. Nat. Biotechnol. 18:97-100.[CrossRef][Medline] |
| 20. | Gray, C. G., S. C. Cowley, K. K. Cheung, and F. E. Nano. 2002. The identification of five genetic loci of Francisella novicida associated with intracellular growth. FEMS Microbiol. Lett. 215:53-56.[CrossRef][Medline] |
| 21. | Green, M., G. Choules, D. Rogers, and R. W. Titball. 2005. Efficacy of the live attenuated Francisella tularensis vaccine (LVS) in a murine model of disease. Vaccine 23:2680-2686.[CrossRef][Medline] |
| 22. | Isherwood, K. E., R. W. Titball, D. H. Davies, P. L. Felgner, and W. J. Morrow. 2005. Vaccination strategies for Francisella tularensis. Adv. Drug Deliv. Rev. 57:1403-1414.[CrossRef][Medline] |
| 23. | Kadokura, H., F. Katzen, and J. Beckwith. 2003. Protein disulfide bond formation in prokaryotes. Annu. Rev. Biochem. 72:111-135.[CrossRef][Medline] |
| 24. | Kadull, P. J., H. R. Reames, L. L.Coriell, and L. Foshay. 1950. Studies on tularemia. V. Immunization of man. J. Immunol. 65:425-435. |
| 25. | Karlsson, J., R. G. Prior, K. Williams, L. Lindler, K. A. Brown, N. Chatwell, K. Hjalmarsson, N. Loman, K. A. Mack, M. Pallen, M. Popek, G. Sandstrom, A. Sjostedt, T. Svensson, I. Tamas, S. G. Andersson, B. W. Wren, P. C. Oyston, and R. W. Titball. 2000. Sequencing of the Francisella tularensis strain Schu 4 genome reveals the shikimate and purine metabolic pathways, targets for the construction of a rationally attenuated auxotrophic vaccine. Microb. Comp. Genomics 5:25-39.[CrossRef][Medline] |
| 26. | Kawula, T. H., J. D. Hall, J. R. Fuller, and R. R. Craven. 2004. Use of transposon-transposase complexes to create stable insertion mutant strains of Francisella tularensis LVS. Appl. Environ. Microbiol. 70:6901-6904. |
| 27. | Kieffer, T. L., S. Cowley, F. E. Nano, and K. L. Elkins. 2003. Francisella novicida LPS has greater immunobiological activity in mice than F. tularensis LPS, and contributes to F. novicida murine pathogenesis. Microbes Infect. 5:397-403.[CrossRef][Medline] |
| 28. | Koonin, E. V., and M. Y. Galperin. 2003. Sequence-evolution-function: computational approaches in comparative genomics. Kluwer Academic, Boston, MA. |
| 29. | Kudelina, R. I. 1978. Sensitivity of the causative agent of tularemia to antibiotics. Antibiotiki 23:710-714.[Medline] |
| 30. | Kuoppa, K., A. Forsberg, and A. Norqvist. 2001. Construction of a reporter plasmid for screening in vivo promoter activity in Francisella tularensis. FEMS Microbiol. Lett. 205:77-81.[CrossRef][Medline] |
| 31. | Lai, X. H., I. Golovliov, and A. Sjostedt. 2004. Expression of IglC is necessary for intracellular growth and induction of apoptosis in murine macrophages by Francisella tularensis. Microb. Pathog. 37:225-230.[Medline] |
| 32. | Larsson, P., P. C. Oyston, P. Chain, M. C. Chu, M. Duffield, H. H. Fuxelius, E. Garcia, G. Halltorp, D. Johansson, K. E. Isherwood, P. D. Karp, E. Larsson, Y. Liu, S. Michell, J. Prior, R. Prior, S. Malfatti, A. Sjostedt, K. Svensson, N. Thompson, L. Vergez, J. K. Wagg, B. W. Wren, L. E. Lindler, S. G. Andersson, M. Forsman, and R. W. Titball. 2005. The complete genome sequence of Francisella tularensis, the causative agent of tularemia. Nat. Genet. 37:153-159.[CrossRef][Medline] |
| 33. | Lauriano, C. M., J. R. Barker, S. S. Yoon, F. E. Nano, B. P. Arulanandam, D. J. Hassett, and K. E. Klose. 2004. MglA regulates transcription of virulence factors necessary for Francisella tularensis intraamoebae and intramacrophage survival. Proc. Natl. Acad. Sci. USA 101:4246-4249. |
| 34. | McCrumb, F. R. 1961. Aerosol infection of man with Pasteurella tularensis. Bacteriol. Rev. 25:262-267. |
| 35. | Nano, F. E., N. Zhang, S. C. Cowley, K. E. Klose, K. K. Cheung, M. J. Roberts, J. S. Ludu, G. W. Letendre, A. I. Meierovics, G. Stephens, and K. L. Elkins. 2004. A Francisella tularensis pathogenicity island required for intramacrophage growth. J. Bacteriol. 186:6430-6436. |
| 36. | Oyston, P. C., and J. E. Quarry. 2005. Tularemia vaccine: past, present and future. Antonie Leeuwenhoek 87:277-281.[CrossRef][Medline] |
| 37. | Pamer, E. G. 2004. Immune responses to Listeria monocytogenes. Nat. Rev. Immunol. 4:812-823.[CrossRef][Medline] |
| 38. | Pammit, M. A., E. K. Raulie, C. M. Lauriano, K. E. Klose, and B. P. Arulanandam. 2006. Intranasal vaccination with a defined attenuated Francisella novicida strain induces gamma interferon-dependent antibody-mediated protection against tularemia. Infect. Immun. 74:2063-2071. |
| 39. | Reed, L. J., and H. Muench. 1935. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497. |
| 40. | Sam-Yellowe, T. Y. 1992. Molecular factors responsible for host cell recognition and invasion in Plasmodium falciparum. J. Protozool. 39:181-189.[Medline] |
| 41. | Saslaw, S., H. T. Eigelsbach, J. A. Prior, H. E. Wilson, and S. Carhart. 1961. Tularemia vaccine study. II. Respiratory challenge. Arch. Intern. Med. 107:702-714.[Medline] |
| 42. | Shen, H., W. Chen, and J. W. Conlan. 2004. Mice sublethally infected with Francisella novicida U112 develop only marginal protective immunity against systemic or aerosol challenge with virulent type A or B strains of F. tularensis. Microb. Pathog. 37:107-110.[CrossRef][Medline] |
| 43. | Shen, H., W. Chen, and J. W. Conlan. 2004. Susceptibility of various mouse strains to systemically- or aerosol-initiated tularemia by virulent type A Francisella tularensis before and after immunization with the attenuated live vaccine strain of the pathogen. Vaccine 22:2116-2121.[CrossRef][Medline] |
| 44. | Tarnvik, A. 1989. Nature of protective immunity to Francisella tularensis. Rev. Infect. Dis. 11:440-451.[Medline] |
| 45. | Tempel, R., K. Geddes, and F. Heffron. 2003. Presented at the Fourth International Conference on Tularemia, Bath, United Kingdom. |
| 46. | Tseng, C. P., C. C. Yu, H. H. Lin, C. Y. Chang, and J. T. Kuo. 2001. Oxygen- and growth rate-dependent regulation of Escherichia coli fumarase (FumA, FumB, and FumC) activity. J. Bacteriol. 183:461-467. |
| 47. | Twine, S., M. Bystrom, W. Chen, M. Forsman, I. Golovliov, A. Johansson, J. Kelly, H. Lindgren, K. Svensson, C. Zingmark, W. Conlan, and A. Sjostedt. 2005. A mutant of Francisella tularensis strain SCHU S4 lacking the ability to express a 58-kilodalton protein is attenuated for virulence and is an effective live vaccine. Infect. Immun. 73:8345-8352. |
| 48. | van der Velden, A. W., S. W. Lindgren, M. J. Worley, and F. Heffron. 2000. Salmonella pathogenicity island 1-independent induction of apoptosis in infected macrophages by Salmonella enterica serotype Typhimurium. Infect. Immun. 68:5702-5709. |
| 49. | Wu, T. H., J. A. Hutt, K. A. Garrison, L. S. Berliba, Y. Zhou, and C. R. Lyons. 2005. Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A. Infect. Immun. 73:2644-2654. |
| 50. | Zusman, T., M. Feldman, E. Halperin, and G. Segal. 2004. Characterization of the icmH and icmF genes required for Legionella pneumophila intracellular growth, genes that are present in many bacteria associated with eukaryotic cells. Infect. Immun. 72:3398-3409. |
This article has been cited by other articles:
), liver (
), and lungs (
) were harvested at 1, 3, 5, 7, and 28 days p.i. Bacteria were liberated from the tissues and enumerated. Each point shows the results for three mice.